2-stage study of pracinostat + azacitidine in patients with high/very high risk MDS by R-IPSS who are candidate for azacitidine treatment

IRB/UVA Tracking #
20170
Phase
II
Primary purpose
Treatment
Cancer PI
Michael Keng
Status
OPEN TO ACCRUAL